LIQUID forms of kinase INHIBITORS Pharmaceutical purity Make sure it's effective Extrapolation of results

changing Paradigms new opportunities non-standard solutions other efficiency

Contact us

solid forms

...think of pharmacokinetics as a drug's journey through the body as it goes through four distinct phases: absorption, distribution, metabolism, and elimination (ADME)...

liquid forms

...any drug administered intravenously has an absolute bioavailability of F=1. The same drug administered by other routes always has a bioavailability of less than 1 (F<1)...

...a concept that offers a new perspective on treatment...

OUR PRODUCTS

Axitinib*LS

Afatinib*LS

Palbociclib*LS

Trametinib*LS

ONC201*LS

ONC212*LS

Fascaplysine*LS

Paxalisib*LS

Nintedanib*LS

CD47/TNFα

sB24M NCT04895566 mAb CD47/TNFa

 

sB37M oral long acting Insulin glargine

 

sB53M rectal suppositories Insulin glargine

Contact Us

  • Mail

    info@sbpm.swiss

Information

All statements and expressions on the site are the exclusive opinion of the biopharmaceutical startup SWISS BIOPHARMA MED Sàrl and are subject to change without notice.

The information contained on this site has been partly verified independently.

The Information may not be reproduced, redistributed, published, or passed on to any other person, directly or indirectly, in whole or in part, for any purpose.

The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country, or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The Information is not for publication, release, or distribution in the United States, EU, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

Information contained herein contains "forward-looking statements."

Any statements that express or involve discussions concerning predictions, expectations, objectives, goals, beliefs, plans, projections, assumptions or future events, or performance are not statements of facts and may be "forward-looking statements."

Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve some risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.

Forward-looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", and "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.

Although the SWISS BIOPHARMA MED Sàrl believes that the expectations reflected in the forward-looking statements are reasonable, the SWISS BIOPHARMA MED Sàrl cannot guarantee future results, levels of activity, performance, or achievements.